Casma Therapeutics Announces $50 Million Series B Financing
PRIVATESep 10, 2020
Amount Raised
$50 Million
Round Type
Series B
CambridgeBiotechnologyHealth CareTherapeutics
Description
Casma Therapeutics, Inc., a biotechnology company harnessing autophagy and the lysosome to design powerful new medicines, today announced the completion of a $50 million Series B financing.
Who else raised in Therapeutics and Biotechnology around the same time
Companies in the same sectors as Casma Therapeutics that raised within 45 days of this round, from Fundz verified event records.
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce★★★★★4.8/5 on G2
Company Information
Company
Casma Therapeutics
Location
Cambridge, Maryland, United States
About
Casma Therapeutics, Inc. is developing novel cellular degradation approaches based on the autophagy pathway to open new target areas for drug discovery and development that will profoundly impact the lives of patients. Autophagy is a conserved cellular process that contributes to overall cellular homeostasis. The autophagy machinery targets large and complex disease targets such as organelles, protein aggregates and large signaling complexes and before directing them to the lysosome for elimination. By selectively degrading disease targets by autophagy, Casma expects to arrest or reverse the progression of disease in multiple oncology, inflammation, neurodegeneration, and metabolic disorders. For more information, please visit Casma’s new website, www.casmatx.com.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Casma Therapeutics raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.